logo-loader
viewSeelos Therapeutics

Roth Capital reiterates Buy rating and $8 price target on Seelos Therapeutics following second quarter pipeline update

Anticipation is high for Seelos's SLS-005 drug, which is centered around the use of trehalose, a natural, small molecule composed of two linked sugars that can cross the blood-brain barrier

Brain highlighted
Roth said Seelos are “busy beavers continue to push forward with exciting updates to the SLS-005 program”

Analysts at Roth Capital have reiterated a Buy rating and $8 price target for shares in Seelos Therapeutics Inc (NASDAQ:SEEL) following the firm’s second quarter pipeline update, released on Thursday, noting that the “busy beavers continue to push forward with exciting updates to the SLS-005 program.”

In a note to clients, the Roth analysts said that after a busy first half of 2019, they see two catalysts that will give Seelos the opportunity to execute and build momentum in the third quarter – the first patient dosing in Ph2b/3 study of its SLS-005 drug in Sanfilippo Syndrome sufferers; and the initiation of PK/PD and DDI studies in suicidality for its SLS-002 drug.

READ: Seelos Therapeutics to embark on two key clinical trials in the third quarter

They pointed out that anticipation is high for the SLS-005 program, which is centered around the use of trehalose, a natural, small molecule composed of two linked sugars that can cross the blood-brain barrier, to target the central nervous system and other diseases caused by formation of toxic protein aggregates.

The analysts estimate peak sales for SLS-005 in Sanfilippo Syndrome in the US to be $423.5 million based on estimates of 4,600 patients, with an 80% diagnosis rate, and assuming a 2022 launch in the US market, with an initial market penetration rate of 2% growing to 40% by 2028.

Seelos has also said it will further develop SLS-005 in other neurological indications such as oculopharyngeal muscular dystrophy (OPMD).

The Roth analysts said they forecast peak sales for SLS-005 in OPMD in the US to be $231.5 million, based on an estimated prevalence rate of 1:100,000, and assuming a 2022 launch in the US market, with an initial market penetration rate of 1% growing to 32% by 2028.

They also estimate peak sales for SLS-002 in acute suicidality in the US to be $1.68 billion based on the estimated 400,000 adults admitted to the hospital growing by 10% annually, and assuming a 2024 launch in the US market.

Seelos shares were trading at $1.52 in afternoon Nasdaq trade on Friday.

Quick facts: Seelos Therapeutics

Price: 1.07 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $28.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read